Biotechnology
Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report
Highlights: * Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation * Strengthening profile at investment, scientific and clinical conferences * Dr David Stamler appointed Chief Executive Officer * Cash balance as at 31 March 2021 of A$32.8M MELBOURN...
2021-04-29 20:30
6392
Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing
SAN FRANCISCO, April 29, 2021 /PRNewswire/ -- Life Whisperer, the fertility arm of AI healthcare company Presagen, has made a significant breakthrough in using artificial intelligence to non-invasively help embryologists rank and select genetically healthy embryos in IVF. Currently, PGT-A geneti...
2021-04-29 19:47
2967
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation ofthe Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of n...
2021-04-29 08:34
3886
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2021-04-29 08:00
5639
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2
- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...
2021-04-28 20:00
1985
CROs dMed and Clinipace Merge to Accelerate Customer Success
SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...
2021-04-28 20:00
3943
Turn Biotechnologies completes latest round of funding
Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest...
2021-04-28 19:50
3695
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
PISCATAWAY, N.J., April 28, 2021 /PRNewswire/ -- GenScript®
2021-04-28 19:30
3061
Samsung Biologics Reports First Quarter 2021 Financial Results
* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...
2021-04-28 16:37
4891
TCI Co., Ltd. becomes Asia's first biotechnology company whose climate ambitions are validated by SBTi
TAIPEI, April 27, 2021 /PRNewswire/ -- TCI Co., Ltd. (8436. TWO), the leading nutraceutical ODM company, announced onApril 22nd that it is finally, after six months of review, recognized by the Science Based Targets Initiative (SBTi) as "committed" to aligning its actions to reduce greenhouse ...
2021-04-27 15:53
3039
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...
2021-04-27 09:23
2749
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" inFrontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administrati...
2021-04-27 09:00
3641
Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer
SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...
2021-04-26 22:08
3921
PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
DAEJEON, South Korea, April 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for ...
2021-04-26 20:00
1928
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...
2021-04-26 19:00
2245
One-Stop CLIA Solution with Open Systems and Resources Makes Evolution to Emerging World Healthcare Systems
* Advanced, flexible cooperation models delivered by one-stop CLIA solution can boost government industrialization plans, laboratory technology updates, reagent R&D and localization, and even more investment flows to the industry * COVID-19 NAb Test CLIA Solution coupled with COVID-19 Ag Self ...
2021-04-26 15:17
2529
Associates of Cape Cod, Inc. announces launch of PyroSmart NextGen™ Recombinant LAL Reagent
EAST FALMOUTH, Mass., April 23, 2021 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a Seikagaku Group Company, announces the launch of a new, innovative, sustainable recombinant LAL reagent, PyroSmart NextGen™ for Bacterial Endotoxin Testing (BET). The new LAL reagent is sustainably produced...
2021-04-23 22:30
4803
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...
2021-04-23 20:00
5636
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...
2021-04-23 15:00
2588
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...
2021-04-22 21:47
4153
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 308 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 304 media titles]
2026-02-26 19:57
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
9087
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2026-02-20 07:27
8380